Diabetes cell therapy firms Sernova and Seraxis to merge

What's the deal? SernovaDealroom has a profile for this one. Try Dealroom → and Seraxis, two biotechs developing cell therapies for diabetes, plan to merge. The combined company aims to advance treatments that have been in development for decades.

What's the endgame? Both firms are pursuing cell-based therapies to treat diabetes. By combining, they intend to work together to move those programs forward.

The signal: The merger reflects consolidation among smaller biotechs chasing the long-sought goal of a cell therapy for diabetes, pooling resources to close in on the clinic.

Read more: endpoints.news

Image credit: Generated with Gemini